(Q40828883)

English

Dexrazoxane (ICRF-187).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

Dexrazoxane (ICRF-187). (English)

1 reference

Europe PubMed Central

24 September 2017

1

object named as

Weiss G

1 reference

Europe PubMed Central

24 September 2017

author name string

Loyevsky M

2

1 reference

Europe PubMed Central

24 September 2017

Gordeuk VR

3

1 reference

Europe PubMed Central

24 September 2017

publication date

1 January 1999

1 reference

Europe PubMed Central

24 September 2017

General Pharmacology

1 reference

Europe PubMed Central

24 September 2017

32

1 reference

Europe PubMed Central

24 September 2017

1

1 reference

Europe PubMed Central

24 September 2017

155-158

1 reference

Europe PubMed Central

24 September 2017

Strategies for prevention of anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187)

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Iron sequestration by macrophages decreases the potential for extracellular hydroxyl radical formation

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mode of Action of the Cytostatic Agent ‘ICRF 159’

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro effects of three iron chelators on mitogen-activated lymphocytes: identification of differences in their mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Linkage of cell-mediated immunity to iron metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0306-3623(98)00100-1

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40828883&oldid=1507864018"